[go: up one dir, main page]

WO2002007732A3 - Use of panaxatriol for stimulation angiogenesis - Google Patents

Use of panaxatriol for stimulation angiogenesis Download PDF

Info

Publication number
WO2002007732A3
WO2002007732A3 PCT/GB2001/003360 GB0103360W WO0207732A3 WO 2002007732 A3 WO2002007732 A3 WO 2002007732A3 GB 0103360 W GB0103360 W GB 0103360W WO 0207732 A3 WO0207732 A3 WO 0207732A3
Authority
WO
WIPO (PCT)
Prior art keywords
panaxatriol
angiogenesis
stimulation
stimulation angiogenesis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2001/003360
Other languages
French (fr)
Other versions
WO2002007732A2 (en
Inventor
Tai-Ping Fan
Shiladitya Sengupta
Sue-Anne Ee Shiow Toh
Ngok Shun Ricky Wong
Hin Wing Yueng
Hi Wun Leung
Ying Kit Patrick Yue
Yuk Ling Daisy Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge University Technical Services Ltd CUTS
Hong Kong Baptist University HKBU
Original Assignee
Cambridge University Technical Services Ltd CUTS
Hong Kong Baptist University HKBU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0018388A external-priority patent/GB0018388D0/en
Priority claimed from GBGB0105613.4A external-priority patent/GB0105613D0/en
Application filed by Cambridge University Technical Services Ltd CUTS, Hong Kong Baptist University HKBU filed Critical Cambridge University Technical Services Ltd CUTS
Priority to AU2001275707A priority Critical patent/AU2001275707A1/en
Publication of WO2002007732A2 publication Critical patent/WO2002007732A2/en
Publication of WO2002007732A3 publication Critical patent/WO2002007732A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

According to the invention we provide use of panaxatriol for the treatment of conditions requiring stimulation of angiogenesis, and use of panaxatriol in the manufacture of medicaments for such treatment. Preferaby the panaxatriol is the naturally-occurrig ginsenoside Rg1.
PCT/GB2001/003360 2000-07-26 2001-07-26 Use of panaxatriol for stimulation angiogenesis Ceased WO2002007732A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001275707A AU2001275707A1 (en) 2000-07-26 2001-07-26 Use of panaxatriol for stimulation angiogenesis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0018388.9 2000-07-26
GB0018388A GB0018388D0 (en) 2000-07-26 2000-07-26 Pharmaceutically effective compounds and their use
GB0105613.4 2001-03-07
GBGB0105613.4A GB0105613D0 (en) 2001-03-07 2001-03-07 Pharmaceutically effective compounds and their use

Publications (2)

Publication Number Publication Date
WO2002007732A2 WO2002007732A2 (en) 2002-01-31
WO2002007732A3 true WO2002007732A3 (en) 2002-11-07

Family

ID=26244734

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/003360 Ceased WO2002007732A2 (en) 2000-07-26 2001-07-26 Use of panaxatriol for stimulation angiogenesis

Country Status (2)

Country Link
AU (1) AU2001275707A1 (en)
WO (1) WO2002007732A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10158281A1 (en) * 2001-11-19 2003-05-28 Mediwirk Gmbh Pharmaceutical preparation comprises ginsenoside enclosed in micro-shell, e.g. liposome, providing targeted and controlled delivery, useful e.g. in treatment of liver tumors, diabetes mellitus or hypertension
ES2716528T3 (en) 2003-06-23 2019-06-13 Telomerase Activation Sciences Inc Compositions to increase telomerase activity
US9248088B2 (en) 2003-06-25 2016-02-02 Telomerase Activation Sciences, Inc. Compositions and methods for skin conditioning
CN100594910C (en) * 2004-06-03 2010-03-24 昆明香格喜玛生物技术有限责任公司 Compound panoxatriol saponin with physiological activity and its preparation and use
MX2007000562A (en) * 2004-07-16 2007-03-30 Univ Columbia Compounds and their preparation for the treatment of alzheimer's disease by inhibiting beta-amyloid peptide production.
GB2461037A (en) * 2008-06-17 2009-12-23 Elias Bouras A method of treating alopecia using a composition comprising a cardiac glycoside
PL2437606T3 (en) 2009-05-18 2017-07-31 Telomerase Activation Sciences, Inc. Compositions and methods for increasing telomerase activity
CN104644650A (en) * 2013-11-18 2015-05-27 富力 Application of 20(R)-ginsenoside Rg3 in preparation of medicine for improving and/or treating alopecia
CN104706697A (en) * 2013-12-17 2015-06-17 兰州大学 Application of radix ginseng in inhibition of ras proto-oncogene overexpression
CN104706938A (en) * 2013-12-17 2015-06-17 兰州大学 Application of radix ophiopogonis in inhibition of ras proto-oncogene overexpression
CN104706937B (en) * 2013-12-17 2018-12-21 兰州大学 Shengmai San is inhibiting the application in ras proto-oncogene overexpression
CN104706939A (en) * 2013-12-17 2015-06-17 兰州大学 Pharmaceutical composition for inhibition of ras proto-oncogene overexpression
CN105267619B (en) * 2014-06-07 2018-05-01 兰州大学 The anti-tumor Chinese medicine compound extract that a kind of suppression ras proto-oncogenes are overexpressed
US10679484B2 (en) 2017-02-01 2020-06-09 Fisher Controls International Llc Methods and apparatus for communicating alert notifications using discrete input channels
CN115444611A (en) * 2021-04-02 2022-12-09 苏州大学 Preparation method of barbed silk suture line

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6038314A (en) * 1983-08-10 1985-02-27 Osaka Chem Lab Hair tonic
US5663160A (en) * 1992-09-17 1997-09-02 Lvmh Recherche Cosmetic or dermatological composition containing at least one saponin of the ginsenoside type, and its applications, especially for treating the hair
JPH1036388A (en) * 1996-07-25 1998-02-10 Kureha Chem Ind Co Ltd Synthesis inhibitor containing ginsenoside of protein belonging to hsp 27 family
WO2000015792A2 (en) * 1998-09-14 2000-03-23 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
WO2001046455A2 (en) * 1999-12-21 2001-06-28 Yale University Survivin promotion of angiogenesis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6038314A (en) * 1983-08-10 1985-02-27 Osaka Chem Lab Hair tonic
US5663160A (en) * 1992-09-17 1997-09-02 Lvmh Recherche Cosmetic or dermatological composition containing at least one saponin of the ginsenoside type, and its applications, especially for treating the hair
JPH1036388A (en) * 1996-07-25 1998-02-10 Kureha Chem Ind Co Ltd Synthesis inhibitor containing ginsenoside of protein belonging to hsp 27 family
WO2000015792A2 (en) * 1998-09-14 2000-03-23 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
WO2001046455A2 (en) * 1999-12-21 2001-06-28 Yale University Survivin promotion of angiogenesis

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
CHANG MYUNG-WOONG ET AL: "Effect of ginseng extracts on production of vacuolating toxin by Helicobacter pylori.", JOURNAL OF THE KOREAN SOCIETY FOR MICROBIOLOGY, vol. 32, no. 5, October 1997 (1997-10-01), pages 539 - 551, XP001059834, ISSN: 0253-3162 *
CHEN XIU: "Cardiovascular protection by ginsenosides and their nitric oxide releasing action.", CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, vol. 23, no. 8, 1996, pages 728 - 732, XP000917542, ISSN: 0305-1870 *
CHOI WOONG ET AL: "Inhibitory effects of ginseng saponins on c-fos mRNA expression and the proliferation of rat aortic vascular smooth muscle cells stimulated by angiotensin II.", KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY, vol. 2, no. 2, April 1998 (1998-04-01), pages 201 - 207, XP001059701, ISSN: 1226-4512 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; PAN, XINXIN ET AL: "Protective effect of ginsenosides on acute cerebral ischemia in rats", XP002193266, retrieved from STN Database accession no. 117:226139 CA *
DATABASE WPI Section Ch Week 198515, Derwent World Patents Index; Class B03, AN 1985-089609, XP002193268 *
DATABASE WPI Section Ch Week 199816, Derwent World Patents Index; Class B01, AN 1998-174906, XP002193267 *
FAN ZOU-HENG ET AL: "Enhancement of nitric oxide production from activated macrophages by a purified form of ginsenoside (Rg1).", AMERICAN JOURNAL OF CHINESE MEDICINE, vol. 23, no. 3-4, 1995, pages 279 - 287, XP001059661, ISSN: 0192-415X *
GAO B Y ET AL: "Effect of panaxatriol saponins isolated from Panax notoginseng (PTS) on myocardial ischemic arrhythmia in mice and rats.", ACTA PHARMACEUTICA SINICA, vol. 27, no. 9, 1992, pages 641 - 644, XP001059467 *
JIANG Y. ET AL: "Calcium channel blockade and anti-free-radical actions of panaxatriol saponins in cultured myocardiocytes.", ACTA PHARMACOLOGICA SINICA, (1996) 17/2 (138-141)., XP001059690 *
KIM DO HOON ET AL: "Inhibition of stress-induced plasma corticosterone levels by ginsenosides in mice: Involvement of nitric oxide.", NEUROREPORT, vol. 9, no. 10, 13 July 1998 (1998-07-13), pages 2261 - 2264, XP001059662, ISSN: 0959-4965 *
LI J Q ET AL: "Effect of age and ginsenoside Rg1 on nitric oxide content and nitric oxide synthase activity of cerebral cortex in rats.", YAOXUE XUEBAO, vol. 32, no. 4, 1997, pages 251 - 254, XP001059699, ISSN: 0513-4870 *
LI L ET AL: "EFFECTS OF PANAX NOTOGINSENG SAPONINS ON ACUTE CEREBRAL ISCHEMIA", ZHONGGUO YAOLIXUE TONGBAO - CHINESE PHARMACOLOGICAL BULLETIN, LINCHUANG YAOLI YANJIUSUO, HEFEI, CN, vol. 7, no. 1, 1991, pages 56 - 69, XP001059707, ISSN: 1001-1978 *
LI X ET AL: "PROTECTIVE EFFECTS OF PANAX-NOTOGINSENG SAPONINS ON EXPERIMENTAL MYOCARDIAL INJURY INDUCED BY ISCHEMIA AND REPERFUSION IN RAT", ACTA PHARMACOLOGICA SINICA, vol. 11, no. 1, 1990, pages 26 - 29, XP001059665, ISSN: 0253-9756 *
LI XUE-JUN ET AL: "Protective effects of panaxatriol saponins isolated from Panax notoginseng (PTS) on ischemic-reperfused injury and arrhythmia in isolated rat hearts.", ZHONGGUO YAOLIXUE YU DULIXUE ZAZHI, vol. 6, no. 4, 1992, pages 272 - 274, XP001059697, ISSN: 1000-3002 *
LIU, M. ET AL: "Protective effects of ginsenoside Rb1 and Rg1 on cultured hippocampal neurons", YAOXUE XUEBAO (1995), 30(9), 674-8, XP001059708 *
NANJING YIXUEYUAN XUEBAO (1992), 12(3), 237-9 *
SENGUPTA SHILADITYA ET AL: "Angiogenesis is promoted by ginsenoside Rg1 through the NOSIII pathway.", FASEB JOURNAL, vol. 15, no. 5, 8 March 2001 (2001-03-08), Annual Meeting of the Federation of American Societies for Experimental Biology on Experimental Biology 2001;Orlando, Florida, USA; March 31-April 04, 2001, pages A934, XP001059785, ISSN: 0892-6638 *
WEN, TONG-CHUN ET AL: "Ginseng root prevents learning disability and neuronal loss in gerbils with 5-minute forebrain ischemia", ACTA NEUROPATHOL. (1996), VOLUME DATE 1996, 91(1), 15-22, XP001059706 *
YAMAMOTO, MASAHIRO ET AL: "The stimulatory effects of ginseng saponins on proliferation and DNA synthesis of human vascular endothelial cells and skin fibroblasts in relation to cytokines or growth factors", NISSEI BYOIN IGAKU ZASSHI (1998), 26(1), 39-42, XP001059784 *
ZHANG Y-G ET AL: "INFLUENCES OF GINSENOSIDES RB1 AND RG1 ON REVERSIBLE FOCAL BRAIN ISCHEMIA IN RATS", ZHONGUA YAOLI XUEBAO - ACTA PHARMACOLOGICA SINICA, SHANGHAI, CN, vol. 17, no. 1, January 1996 (1996-01-01), pages 44 - 48, XP002933193, ISSN: 0253-9756 *

Also Published As

Publication number Publication date
AU2001275707A1 (en) 2002-02-05
WO2002007732A2 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
WO2002007732A3 (en) Use of panaxatriol for stimulation angiogenesis
AU2001271973A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
IL154888A (en) Non-aqueous pharmaceutical gel composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid and its use in the manufacture of a medicament for treatment of psoriasis
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
HUP0102337A3 (en) Process for preparation of compositions for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the upper respiratory tract and/or the ear
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
CA2373794A1 (en) Compositions and uses of et743 for treating cancer
WO2001074853A3 (en) Methods and products for regulating cell motility
CA2245123A1 (en) Use of rosaceae plant extract as a bradykinin antagonist
AUPQ879500A0 (en) Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
WO2003039444A3 (en) Topical use of cytokines and/or chemokines for the treatment of viral or mykotic skin diseases or tumoral diseases
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
AU2002363973A8 (en) Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
GB9923078D0 (en) Sapogenin derivatives and their use
EP1806144A3 (en) Use of SARP-1 for the treatment and/or prevention of scleroderma
WO2003007876A3 (en) N-fatty acid-amino acid conjugates and therapeutic uses
EP1303300A4 (en) Compositions and methods for treatment of candidiasis
AU2002348299A1 (en) Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions
WO2002019962A3 (en) Therapeutic and cosmetic uses of heparanases
WO2000061125A3 (en) Osanetant in the treatment of mood disorders
WO2000047192A3 (en) UBIQUINONE QnFOR THE TREATMENT OF PAINS
WO2003039455A3 (en) Methods of treating endometreosis
MD980129A (en) Antiherpetic remedy
MD916G2 (en) Ungent for stomatologic deseases treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2003131335

Country of ref document: RU

Kind code of ref document: A

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP